We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation.
- Authors
Ferra Coll, Christelle; Morgades de la Fe, Mireia; Prieto García, Laura; Vaz, Carlos Pinho; Heras Fernando, María Inmaculada; Bailen Almorox, Rebeca; Garcia‐Cadenas, Irene; Calabuig Muñoz, Marisa; Ripa, Teresa Zudaire; Zanabili Al‐Sibai, Joud; Novoa, Sandra; Aguado, Beatriz; Torrent Catarineu, Anna; López‐Godino, Oriana; Martino Bofarull, Rodrigo; Kwon, Mi; Campos Júnior, Antonio; Caballero Barrigón, Dolores; Ribera Santasusana, Josep‐Maria
- Abstract
The outcomes of patients with acute lymphoblastic leukaemia (ALL) presenting relapse after allogeneic stem cell transplant (allo‐SCT) are poor, with few data available in this setting. Objective and Methods: To evaluate the outcomes of patients with ALL presenting relapsed after allo‐SCT, we performed a retrospective study including 132 from 11 centres in Spain. Results: Therapeutic strategies consisted of palliative treatment (n = 22), chemotherapy (n = 82), tyrosine kinase inhibitors (n = 26), immunotherapy with inotuzumab and/or blinatumumab (n = 19), donor lymphocyte infusions (n = 29 pts), second allo‐SCT (n = 37) and CAR T therapy (n = 14). The probability of overall survival (OS) at 1 and 5 years after relapse was 44% (95% confidence interval [CI]: 36%; 52%) and 19% (95% CI: 11%; 27%). In the 37 patients undergoing a second allo‐SCT, the 5‐year estimated OS probability was 40% [22%; 58%]. Younger age, recent allo‐SCT, late relapse, 1st complete remission at 1st allo‐SCT and chronic graft‐versus‐host disease confirmed their positive impact on survival in the multivariable analysis. Conclusion: Despite the poor prognosis of patients with ALL presenting relapse after a first allo‐SCT, some can be satisfactorily rescued and a second allo‐SCT still remains a valid option for selected patients. Moreover, emerging therapies really might improve ALL patients outcome when relapsing after an allo‐SCT.
- Subjects
SPAIN; LYMPHOBLASTIC leukemia; STEM cell transplantation; ACUTE leukemia; PROGNOSIS
- Publication
European Journal of Haematology, 2023, Vol 110, Issue 6, p659
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13947